Radioactive Peptide Therapy for Neuroendocrine Cancer That Has Spread to the Abdomen
PRRT with Lu-177 DOTATATE showed limited tumor shrinkage in peritoneal neuroendocrine disease but carried risk of intestinal complications.
Quick Facts
What This Study Found
PRRT showed limited response in peritoneal/mesenteric neuroendocrine disease (stable volumes) despite responses in liver metastases, with digestive complication risks.
Key Numbers
N=20; 17 with peritoneal carcinomatosis; functional response rate: PC/MF 18.7% vs liver 38%; 8% of all PRRT patients needed unplanned ED care.
How They Did This
Prospective study of 20 patients with sequential [68Ga]DOTATOC PET/CT before, during, and after [177Lu]DOTATATE PRRT.
Why This Research Matters
Peritoneal neuroendocrine disease is particularly difficult to treat — understanding PRRT's limitations here guides treatment expectations.
The Bigger Picture
This identifies peritoneal disease as a relative resistance point for PRRT, suggesting combination approaches or alternative strategies may be needed.
What This Study Doesn't Tell Us
Small sample (20 patients). No control group. Variable disease burden and prior treatments.
Questions This Raises
- ?Would higher PRRT doses improve peritoneal response?
- ?Should peritoneal neuroendocrine disease be treated with combined PRRT and surgery?
Trust & Context
- Key Stat:
- 20 patients Sequential PET/CT monitoring showed peritoneal disease volumes remained stable despite PRRT
- Evidence Grade:
- Small prospective cohort with imaging endpoints — informative but limited by sample size and absence of control group.
- Study Age:
- Published in 2025, addressing a specific gap in PRRT efficacy data for peritoneal disease.
- Original Title:
- Neuroendocrine peritoneal disease and [177Lu]DOTATATE peptide receptor radionuclide therapy: a therapeutic challenge with potential clinical complications.
- Published In:
- European journal of nuclear medicine and molecular imaging, 52(10), 3682-3689 (2025)
- Authors:
- Poterszman, Nathan, Baltzinger, Philippe, Mamulashvili Bessac, Darejan, Pham Van, Floriane, Goichot, Bernard, Mertz, Luc, Addeo, Pietro, Brigand, Cecile, Imperiale, Alessio
- Database ID:
- RPEP-13094
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
What is PRRT?
Peptide receptor radionuclide therapy — a targeted radiation treatment that delivers radioactive molecules to neuroendocrine tumor cells via their surface receptors.
Does PRRT work for cancer that has spread to the abdomen?
This study found limited response in peritoneal disease compared to liver metastases, suggesting peritoneal spread is harder to treat with PRRT alone.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13094APA
Poterszman, Nathan; Baltzinger, Philippe; Mamulashvili Bessac, Darejan; Pham Van, Floriane; Goichot, Bernard; Mertz, Luc; Addeo, Pietro; Brigand, Cecile; Imperiale, Alessio. (2025). Neuroendocrine peritoneal disease and [177Lu]DOTATATE peptide receptor radionuclide therapy: a therapeutic challenge with potential clinical complications.. European journal of nuclear medicine and molecular imaging, 52(10), 3682-3689. https://doi.org/10.1007/s00259-025-07212-3
MLA
Poterszman, Nathan, et al. "Neuroendocrine peritoneal disease and [177Lu]DOTATATE peptide receptor radionuclide therapy: a therapeutic challenge with potential clinical complications.." European journal of nuclear medicine and molecular imaging, 2025. https://doi.org/10.1007/s00259-025-07212-3
RethinkPeptides
RethinkPeptides Research Database. "Neuroendocrine peritoneal disease and [177Lu]DOTATATE peptid..." RPEP-13094. Retrieved from https://rethinkpeptides.com/research/poterszman-2025-neuroendocrine-peritoneal-disease-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.